Skip to main content
Atrás
Watch Compare

Whitehawk Therapeutics, Inc.

Calidad de datos: 100%
WHWK
Nasdaq Manufacturing Chemicals
$3.39
▼ $0.16 (-4.51%)
Cap. Mercado: 165.19 M
Precio
$3.50
Cap. Mercado
165.19 M
Rango del Día
—
Rango de 52 Semanas
—
Volumen
—
Apertura —
Promedio 50D / 200D
—
Promedio 50D / 200D
—

Quick Summary

Puntos Clave

Revenue grew 58.93% annually over 5 years — strong growth
Negative free cash flow of -97.99 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 131.43%
Capital efficient — spends only 7.73% of revenue on capex

Crecimiento

Revenue Growth (5Y)
58.93%
Above sector avg (1.82%)
Revenue (1Y)-72.50%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-12.51%
Above sector avg (-53.47%)
ROIC-54.90%
Net Margin-288.26%
Op. Margin-1601.12%

Seguridad

Debt / Equity
N/A
Current Ratio16.76
Interest CoverageN/A

Valoración

PE (TTM)
-8.02
Below sector avg (-1.48)
P/B Ratio1.05
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (1364 pares)
Métrica Acción Mediana del Sector
P/E -8.0 -1.5
P/B 1.1 1.6
ROE % -12.5 -53.5
Net Margin % -288.3 -41.5
Rev Growth 5Y % 58.9 1.8
D/E — 0.3

Precio Objetivo de Analistas

3 analistas
Hold
Actual
$3.39
+67.2%
Objetivo
$5.67
$4.00
$6.00
$7.00
Pronóstico
P/E Futuro -2.83
EPS Futuro -$1.20
Ingresos Est. 0.0

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2027 -$1.20
-$1.20 – -$1.20
 0.0 1
FY2026 -$1.27
-$1.37 – -$1.16
 0.0 2

Sorpresas de Ganancias

Últimos 4 trimestres
Trimestre EPS Est. EPS Real Sorpresa
Q42025 -$0.27 -$0.34 -25.9%
Q32025 -$0.22 -$0.25 -15.4%
Q22025 -$0.17 -$0.76 -347.1%
Q12025 -$0.23 -$0.36 -58.2%

ETFs Holding This Stock

BRUSX BRUSX
0.58% weight
AVSC logo AVSC Avantis U.S. Small Cap Equity ETF
0.00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -72.50% Revenue Growth (3Y) -45.84%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 58.93% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 7.15 M Net Income (TTM) -20.60 M
ROE -12.51% ROA -11.84%
Gross Margin N/A Operating Margin -1601.12%
Net Margin -288.26% Free Cash Flow (TTM) -97.99 M
ROIC -54.90% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 16.76
Interest Coverage N/A Asset Turnover 0.04
Working Capital 155.19 M Tangible Book Value 157.17 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -8.02 Forward P/E N/A
P/B Ratio 1.05 P/S Ratio 23.12
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -59.32%
Market Cap 165.19 M Enterprise Value 127.26 M
Per Share
EPS (Diluted TTM) -0.33 Revenue / Share 0.15
FCF / Share -2.08 OCF / Share -2.06
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 7.73% FCF Conversion 475.75%
SBC-Adj. FCF -108.03 M Growth Momentum -131.43

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 7.15 M 25.98 M 24.35 M 15.22 M 1.12 M
Net Income -20.60 M -63.69 M -65.77 M -60.51 M -110.09 M
EPS (Diluted) -0.33 -2.36 -2.44 -2.69 —
Gross Profit — — — — —
Operating Income -114.40 M -67.46 M -71.93 M -62.68 M -111.22 M
EBITDA — — — — —
R&D Expenses 90.96 M 51.03 M 48.93 M 32.66 M 19.67 M
SG&A Expenses 29.82 M 36.75 M 44.55 M 40.18 M —
D&A 79,000.0 193,000.0 169,000.0 159,000.0 105,000.0
Interest Expense 0.0 154,000.0 231,000.0 230,000.0 665,000.0
Income Tax 0.0 0.0 0.0 0.0 2,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 150.83 M 70.32 M 132.42 M 184.24 M 157.91 M
Total Liabilities 14.52 M 17.84 M 27.23 M 25.86 M 21.50 M
Shareholders' Equity 136.31 M 52.48 M 105.20 M 158.38 M 136.41 M
Total Debt — — — — —
Cash & Equivalents 37.57 M 28.67 M 62.89 M 39.02 M 148.99 M
Current Assets 149.01 M 61.29 M 124.59 M 180.03 M 151.27 M
Current Liabilities 14.52 M 17.07 M 26.40 M 18.84 M 15.27 M